Dry AMDMAIAStudNCT07170683
Microperimetry Changes in Retinal Function in Macular Disorders
An observational study of Dry AMD and Diabetic Retinopathy (DR), run by University of Nottingham at 1 site in United Kingdom.
Trial summary
The purpose of this study is to measure precisely how sensitive the central part of the retina - the light-sensitive film at the back of the eye, is to light. We will use a special device called the Macular Integrity Assessment (MAIA) microperimetry (MP) system to achieve this, particularly for individuals with… Read more about this study
- Who is it for?
- Ages 21 years and olderHealthy volunteers can take part
- Conditions the study is for
- Dry AMD, Diabetic Retinopathy (DR)
- What is being tested?
- MAIA Microperimetry, Microperimetry and Visual Acuity Measurement (logMAR)
- Type of treatment
- Medical device
- How many people
- 200 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 4 Apr 2025to 30 Aug 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Participants will be recruited from the Medical Retina and Macular clinics of the Queen's Medical Centre. Healthy controls will be recruited from persons accompanying patients to the Eye Clinic, hospital and University staff. Healthy volunteers who are accompanying persons to the clinic will be approached after the patient participant has been approached.
Who may be able to join
- Adult age above 21 years old.
- Signed informed consent
- Visual acuity Log MAR 0.0 to 1.2
- Patients diagnosed with:
- Geographic atrophy (AMD).
- Diabetic without retinopathy, and minimal to moderate non-proliferative diabetic retinopathy (NPDR) with or without presence of macular oedema on optical coherence tomography (OCT)
- Control group of age matched participants without any retinal disease, glaucoma or optic nerve disease in either eye Patients willing to attend follow-up MP examinations. (This does not apply to normal controls who only require one attendance).
Who cannot join
- Moderate to severe cataract (over grade 2) or other cause of opaque optical media that will preclude adequate fundoscopy or MP assessment.
- Previous treatments in the eye with intravitreal therapies of anti-VEGFs or steroids within the previous 6 months, or macular laser photocoagulation
- Active vascular event in either eye any examination time.
- Participants who are unable/unwilling to provide consent
- Participants who are unable to read English fluently
- Normal Controls Inclusion Criteria
Show all 17Show fewer
- Normal controls will include persons who are not diabetic, and do not have glaucoma, any retinal or optic nerve disease.
- Signed informed consent
- Adult age above 21 years old. No upper age limit.
- Visual acuity LogMAR <0.2.
- Controls should be willing to attend once only.
- Moderate to severe cataract (over grade 2) or other cause of opaque optical media
- Previous treatments in the particular eye with intravitreal therapies of anti-VEGFs or steroids within the previous 6 months, or macular laser photocoagulation
- Active/previous vascular event in either eye e.g. retinal arterial or vein occlusion, ischaemic optic neuropathy, or glaucoma
- Persons with diabetes
- Participants who are unable to read English fluently
- Participants who are unable/unwilling to provide consent
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United Kingdom1 site
Nottingham University Hospitals NHS Trust
Nottingham, Notts, NG7 2UH
About this study
Official title: An Investigation of Microperimetry for Monitoring Retinal Function in Selected Macular Disorders
The purpose of this study is to measure precisely how sensitive the central part of the retina - the light-sensitive film at the back of the eye, is to light. We will use a special device called the Macular Integrity Assessment (MAIA) microperimetry (MP) system to achieve this, particularly for individuals with specific retinal conditions. The macula (with the fovea at its very centre) is the part of the retina responsible for our fine detailed vision, colour vision, and maintaining steady gaze on objects (called 'fixation'). Diseases that affect the macula lead to difficulties in seeing clearly.
Macular sensitivity refers to how responsive the macula is to light, including the ability to read and focus on objects. This also determines how well the eye can maintain a steady gaze on objects of interest ('fixation'). While standard eye tests primarily measure vision in the fovea, measuring sensitivity across the wider macula would provide a more complete picture of visual function. Furthermore, we believe that macular sensitivity changes are often one of the earliest signs of retinal diseases, before a person experiences blurry vision. Currently, MP is not used routinely in UK NHS clinical practice.
Read more
The commonest retinal diseases are age-related macular degeneration (AMD) and diabetic retinopathy (DR). There are 2 types of AMD: dry and wet.
- Dry AMD is a condition that affects the central part of the retina (the macula) and can lead to gradual vision loss as people age. This is due to wearing out and loss of the slight sensitive cells in the macula that can make it harder to see fine details, such as reading or recognizing faces.
- Diabetic retinopathy means that diabetes has affected the blood vessels in the retina. In the early stages, the affected blood vessels do not leak. However, progression results in leakage of the blood vessels in the retina, leading to retinal swelling (called diabetic macular oedema [DMO]). Eyes with DMO function less well compared to when there is no swelling.
It is important to investigate these selected common conditions further, in order to find ways of detecting changes earlier, before the patient notices any abnormalities. Such earlier detection may result in better understanding and treatments in the future.
The main goal of this research is to measure macular sensitivity and ability to maintain a steady gaze on specific objects or points in patients with these macular disorders using the MAIA device. These measurements will be compared to changes in the structure of the macula, obtained using advanced imaging techniques like optical coherence tomography (OCT) and OCT angiography (OCTA), which are routinely used in standard clinical practice.
This study will form part of a research/educational thesis, and provide additional data to complement previous research on the topic.
Participants (after consent) will have MP done. In addition, we will assess information from their eye clinic records, including images and scans of the back of the eyes (OCT and OCTA). No treatment interventions are planned as part of this study. Participants standard of care will not be affected.
Participants will have tests done at baseline, and repeated at 6 and 12 months. In addition, we will invite a group of normal controls (i.e. persons who do not have any diseases of the back of their eyes) for comparison. This will ensure validity of our findings. The normal controls will attend only once (at baseline). After consent is obtained, these healthy participants will have MP, and imaging of the macula with OCT.
- Conditions
- Dry AMD, Diabetic Retinopathy (DR)
- Being tested
- MAIA Microperimetry, Microperimetry, Visual Acuity Measurement (logMAR), OCT-A
- Keywords
- retinal sensitivity, microperimetry, diabetic retinopathy, dry AMD, OCT, OCT-A, geographic atrophy
- Medical subject headings
- Diabetic Retinopathy, Geographic Atrophy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MAIA MicroperimetryOther
Microperimetry (MP) is not performed as part of the current NHS patient pathway. We plan testing 2 MP strategies ('standard' vrs 'fast') to determine whether the fast testing strategy is as robust as the standard test strategy. Adopting the fast strategy will reduce time spent on the MP machine to obtain relevant test results. Healthy volunteers (with no retinal disease) are necessary for comparison, and to establish validity of any new findings.
MicroperimetryDevice
Two fully automatic MAIA MP (CenterVue, spa; Padova, Italy) examinations (to obtain retinal sensitivity) shall be performed over the 10° diameter central retinal area for the recruited study participants. The first one will be performed with a fast projection, and the second one with the standard full 4-2 staircase projection strategy. Identification of the PRL area will be automatically calculated at the end of each examination. All patient groups will have identical assessment, at all time points. Healthy volunteers will only have assessments at baseline (one examination only)..
Visual Acuity Measurement (logMAR)Other
Visual acuity will be measured with the ETDRS chart, and with the participant habitual distance correction, and recorded in logMAR notation
OCT-ADevice
OCT and OCT-A examination, as well FAF will be undertaken with the Topcon Triton Plus OCT
| Study group | Role | What they receive |
|---|---|---|
| Participants with dry AMD (including geographic atrophy [GA]) | Participants with dry AMD including GA. MP will be performed in 2 different modalities, a full staircase threshold stimuli projection, and a simplified stimuli projection of 4 fixed levels of stimuli intensity.
OCT and OCT-A will be done with the Topcon Triton. Best habitual corrected distance VA (logMAR) will be recorded. Receives: Other: MAIA Microperimetry; Device: Microperimetry; Other: Visual Acuity Measurement (logMAR); Device: OCT-A | |
| Persons with diabetes without diabetic retinopathy | Participants with diabetes without diabetic retinopathy. MP will be performed in 2 different modalities, a full staircase threshold stimuli projection, and a simplified stimuli projection of 4 fixed levels of stimuli intensity.
OCT and OCT-A will be done with the Topcon Triton. Best habitual corrected distance VA (logMAR) will be recorded. Receives: Other: MAIA Microperimetry; Device: Microperimetry; Other: Visual Acuity Measurement (logMAR); Device: OCT-A | |
| Participants with diabetes with mild to moderate diabetic retinopathy (i.e. non-proliferative DR).. | Participants with diabetes with mild to moderate diabetic retinopathy. MP will be performed in 2 different modalities, a full staircase threshold stimuli projection, and a simplified stimuli projection of 4 fixed levels of stimuli intensity.
OCT and OCT-A will be done with the Topcon Triton. Best habitual corrected distance VA (logMAR) will be recorded. Receives: Other: MAIA Microperimetry; Device: Microperimetry; Other: Visual Acuity Measurement (logMAR); Device: OCT-A | |
| Normal (healthy) controls | Normal controls will include persons who are not diabetic, and do not have glaucoma, any retinal or optic nerve disease.
MP will be performed in 2 different modalities, a full staircase threshold stimuli projection, and a simplified stimuli projection of 4 fixed levels of stimuli intensity.
OCT and OCT-A will be done with the Topcon Triton. Best habitual corrected distance VA (logMAR) will be recorded. Receives: Other: MAIA Microperimetry; Device: Microperimetry; Other: Visual Acuity Measurement (logMAR); Device: OCT-A |
What is being measured
The primary outcome is the main question the study is designed to answer.
Correlations of retinal sensitivity (dB) changes over time, compared with OCT/OCTA measures (change in retinal/choroidal thickness in microns and/or %; % change in choroidal vascularity)
Retinal sensitivity (dB) will be measured with MP. Correlations will be made between retinal sensitivities between each group and normal controls, and over time.
Measured: from enrolment (baseline) to 6 and 12 months
MP BCEA values
Correlations of changes in BCEA (fixation stability in degrees: BCEA@63 and BCEA@95) in the different groups will be analysed similarly, and over time, using a mixed-effects model to account for variability between eyes and between subjects. Quantify deviations from baseline PRL in degrees.
Measured: Baseline compared to 6 and 12 months
Secondary outcomes (1)
Baseline factors relationship to retinal sensitivity (dB) with age (years), disease duration (years) and baseline visual acuity (LogMAR)
Relationship of baseline factors (e.g., age [years], disease duration [years], baseline visual acuity [logMAR]) are predictive of outcomes in retinal sensitivity (dB), fixation stability (BCEA), or fixation (PRL) location. Statistical correlations will be made of retinal sensitivities (dB) between each group(dry AMD, no DR, DR) and normal controls, and over time
Measured: baseline, changes from baseline to 6 and 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Sep 2025
- Study start4 Apr 2025
- Primary completion30 Aug 2026 (estimated)
- Study completion30 Aug 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Dry AMDStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Nottingham
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07170683
- Sponsor's protocol ID
- 24060
- Acronym
- MAIAStud
- Status last verified
- Aug 2025
- First submitted
- 8 Jul 2025
- Last updated
- 12 Sep 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Investigation of Microperimetry for Monitoring Retinal Function in Selected Macular Disorders
- ClinicalTrials.gov ID
- NCT07170683
- Acronym / sponsor ID
- MAIAStud / 24060
- Conditions
- Dry AMD, Diabetic Retinopathy (DR)
- Keywords
- retinal sensitivity, microperimetry, diabetic retinopathy, dry AMD, OCT, OCT-A, geographic atrophy
- Study type
- Observational
- Recruitment status
- Enrolling by invitation
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- University of NottinghamUniversity, hospital or other
- Study start
- 4 Apr 2025 (actual)
- Primary completion
- 30 Aug 2026 (estimated)
- Study completion
- 30 Aug 2026 (estimated)
- First posted
- 12 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to measure precisely how sensitive the central part of the retina - the light-sensitive film at the back of the eye, is to light. We will use a special device called the Macular Integrity Assessment (MAIA) microperimetry (MP) system to achieve this, particularly for individuals with specific retinal conditions. The macula (with the fovea at its very centre) is the part of the retina responsible for our fine detailed vision, colour vision, and maintaining steady gaze on objects (called 'fixation'). Diseases that affect the macula lead to difficulties in seeing clearly.
Macular sensitivity refers to how responsive the macula is to light, including the ability to read and focus on objects. This also determines how well the eye can maintain a steady gaze on objects of interest ('fixation'). While standard eye tests primarily measure vision in the fovea, measuring sensitivity across the wider macula would provide a more complete picture of visual function. Furthermore, we believe that macular sensitivity changes are often one of the earliest signs of retinal diseases, before a person experiences blurry vision. Currently, MP is not used routinely in UK NHS clinical practice.
The commonest retinal diseases are age-related macular degeneration (AMD) and diabetic retinopathy (DR). There are 2 types of AMD: dry and wet.
- Dry AMD is a condition that affects the central part of the retina (the macula) and can lead to gradual vision loss as people age. This is due to wearing out and loss of the slight sensitive cells in the macula that can make it harder to see fine details, such as reading or recognizing faces.
- Diabetic retinopathy means that diabetes has affected the blood vessels in the retina. In the early stages, the affected blood vessels do not leak. However, progression results in leakage of the blood vessels in the retina, leading to retinal swelling (called diabetic macular oedema [DMO]). Eyes with DMO function less well compared to when there is no swelling.
It is important to investigate these selected common conditions further, in order to find ways of detecting changes earlier, before the patient notices any abnormalities. Such earlier detection may result in better understanding and treatments in the future.
The main goal of this research is to measure macular sensitivity and ability to maintain a steady gaze on specific objects or points in patients with these macular disorders using the MAIA device. These measurements will be compared to changes in the structure of the macula, obtained using advanced imaging techniques like optical coherence tomography (OCT) and OCT angiography (OCTA), which are routinely used in standard clinical practice.
This study will form part of a research/educational thesis, and provide additional data to complement previous research on the topic.
Participants (after consent) will have MP done. In addition, we will assess information from their eye clinic records, including images and scans of the back of the eyes (OCT and OCTA). No treatment interventions are planned as part of this study. Participants standard of care will not be affected.
Participants will have tests done at baseline, and repeated at 6 and 12 months. In addition, we will invite a group of normal controls (i.e. persons who do not have any diseases of the back of their eyes) for comparison. This will ensure validity of our findings. The normal controls will attend only once (at baseline). After consent is obtained, these healthy participants will have MP, and imaging of the macula with OCT.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Participants with dry AMD (including geographic atrophy [GA]) | – | Other: MAIA Microperimetry, Device: Microperimetry, Other: Visual Acuity Measurement (logMAR), Device: OCT-AParticipants with dry AMD including GA. MP will be performed in 2 different modalities, a full staircase threshold stimuli projection, and a simplified stimuli projection of 4 fixed levels of stimuli intensity. OCT and OCT-A will be done with the Topcon Triton. Best habitual corrected distance VA (logMAR) will be recorded. |
| Persons with diabetes without diabetic retinopathy | – | Other: MAIA Microperimetry, Device: Microperimetry, Other: Visual Acuity Measurement (logMAR), Device: OCT-AParticipants with diabetes without diabetic retinopathy. MP will be performed in 2 different modalities, a full staircase threshold stimuli projection, and a simplified stimuli projection of 4 fixed levels of stimuli intensity. OCT and OCT-A will be done with the Topcon Triton. Best habitual corrected distance VA (logMAR) will be recorded. |
| Participants with diabetes with mild to moderate diabetic retinopathy (i.e. non-proliferative DR).. | – | Other: MAIA Microperimetry, Device: Microperimetry, Other: Visual Acuity Measurement (logMAR), Device: OCT-AParticipants with diabetes with mild to moderate diabetic retinopathy. MP will be performed in 2 different modalities, a full staircase threshold stimuli projection, and a simplified stimuli projection of 4 fixed levels of stimuli intensity. OCT and OCT-A will be done with the Topcon Triton. Best habitual corrected distance VA (logMAR) will be recorded. |
| Normal (healthy) controls | – | Other: MAIA Microperimetry, Device: Microperimetry, Other: Visual Acuity Measurement (logMAR), Device: OCT-ANormal controls will include persons who are not diabetic, and do not have glaucoma, any retinal or optic nerve disease. MP will be performed in 2 different modalities, a full staircase threshold stimuli projection, and a simplified stimuli projection of 4 fixed levels of stimuli intensity. OCT and OCT-A will be done with the Topcon Triton. Best habitual corrected distance VA (logMAR) will be recorded. |
Who may qualify
- Ages
- 21 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Participants will be recruited from the Medical Retina and Macular clinics of the Queen's Medical Centre. Healthy controls will be recruited from persons accompanying patients to the Eye Clinic, hospital and University staff. Healthy volunteers who are accompanying persons to the clinic will be approached after the patient participant has been approached.
Key inclusion criteria (7 listed)
- Adult age above 21 years old.
- Signed informed consent
- Visual acuity Log MAR 0.0 to 1.2
- Patients diagnosed with:
- Control group of age matched participants without any retinal disease, glaucoma or optic nerve disease in either eye Patients willing to attend follow-up MP examinations. (This does not apply to normal controls who only require one attendance).
Key exclusion criteria (17 listed)
- Moderate to severe cataract (over grade 2) or other cause of opaque optical media that will preclude adequate fundoscopy or MP assessment.
- Previous treatments in the eye with intravitreal therapies of anti-VEGFs or steroids within the previous 6 months, or macular laser photocoagulation
- Active vascular event in either eye any examination time.
- Participants who are unable/unwilling to provide consent
- Participants who are unable to read English fluently
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MAIA MicroperimetryMicroperimetry (MP) is not performed as part of the current NHS patient pathway. We plan testing 2 MP strategies ('standard' vrs 'fast') to determine whether the fast testing strategy is as robust as the standard test strategy. Adopting the fast strategy will reduce time spent on the MP machine to obtain relevant test results. Healthy volunteers (with no retinal disease) are necessary for comparison, and to establish validity of any new findings. | Other | Normal (healthy) controls, Participants with diabetes with mild to moderate diabetic retinopathy (i.e. non-proliferative DR).., Participants with dry AMD (including geographic atrophy [GA]), Persons with diabetes without diabetic retinopathy |
| MicroperimetryTwo fully automatic MAIA MP (CenterVue, spa; Padova, Italy) examinations (to obtain retinal sensitivity) shall be performed over the 10° diameter central retinal area for the recruited study participants. The first one will be performed with a fast projection, and the second one with the standard full 4-2 staircase projection strategy. Identification of the PRL area will be automatically calculated at the end of each examination. All patient groups will have identical assessment, at all time points. Healthy volunteers will only have assessments at baseline (one examination only).. | Device | Normal (healthy) controls, Participants with diabetes with mild to moderate diabetic retinopathy (i.e. non-proliferative DR).., Participants with dry AMD (including geographic atrophy [GA]), Persons with diabetes without diabetic retinopathy |
| Visual Acuity Measurement (logMAR)Visual acuity will be measured with the ETDRS chart, and with the participant habitual distance correction, and recorded in logMAR notation | Other | Normal (healthy) controls, Participants with diabetes with mild to moderate diabetic retinopathy (i.e. non-proliferative DR).., Participants with dry AMD (including geographic atrophy [GA]), Persons with diabetes without diabetic retinopathy |
| OCT-AOCT and OCT-A examination, as well FAF will be undertaken with the Topcon Triton Plus OCT | Device | Normal (healthy) controls, Participants with diabetes with mild to moderate diabetic retinopathy (i.e. non-proliferative DR).., Participants with dry AMD (including geographic atrophy [GA]), Persons with diabetes without diabetic retinopathy |
Primary outcome
Correlations of retinal sensitivity (dB) changes over time, compared with OCT/OCTA measures (change in retinal/choroidal thickness in microns and/or %; % change in choroidal vascularity)
Time frame: from enrolment (baseline) to 6 and 12 months
Retinal sensitivity (dB) will be measured with MP. Correlations will be made between retinal sensitivities between each group and normal controls, and over time.
MP BCEA values
Time frame: Baseline compared to 6 and 12 months
Correlations of changes in BCEA (fixation stability in degrees: BCEA@63 and BCEA@95) in the different groups will be analysed similarly, and over time, using a mixed-effects model to account for variability between eyes and between subjects. Quantify deviations from baseline PRL in degrees.
1 secondary outcome
Baseline factors relationship to retinal sensitivity (dB) with age (years), disease duration (years) and baseline visual acuity (LogMAR)
Time frame: baseline, changes from baseline to 6 and 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Sep 2025.
- Individual participant dataSharing planned: No
Related trials for Dry AMD
Active, not recruitingPhase 1/2
Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration
Age-Related Macular Degeneration
RecruitingObservational study
A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)
Geographic Atrophy Secondary to Age-related Macular Degeneration
RecruitingPhase 1/2
Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration
Dry Age-Related Macular Degeneration, Geographic Atrophy
Active, not recruitingPhase 3
A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)
Geographic Atrophy
Not yet recruitingObservational study
MIND-AMD Study: a Multidisciplinary Investigation of Neuroretinal Damage in Age-related Macular Degeneration.
Age-Related (Dry) Macular Degeneration, Age-Related Macular Degeneration (AMD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Dry AMD and Diabetic Retinopathy (DR), run by University of Nottingham at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 12 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Correlations of retinal sensitivity (dB) changes over time, compared with OCT/OCTA measures (change in retinal/choroidal thickness in microns and/or %; % change in choroidal vascularity) (time frame: from enrolment (baseline) to 6 and 12 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Sep 2025.